CAJ | 학술논문

目的：探讨扶正抗癌方联合化疗治疗非小细胞肺癌的临床疗效。方法对本院2006年7月至2012年6月住院非小细胞肺癌患者67例,按照随机数字表法分为治疗组33例和对照组34例,对照组采用化疗治疗,治疗组在对照组基础上使用扶正抗癌方治疗,治疗2个周期后,观察两组临床疗效、中医症候积分、Karnofsky功能状态评分标准( KPS)评分、毒副反应情况。结果近期临床疗效比较：治疗组有效率为36．36%(12/33),对照组有效率为23．52%(8/34),两组有效率比较不具有统计学意义(χ2=0．776,P>0．05)。中医症状积分改善情况及KPS改善情况比较：治疗组中医症候积分和KPS评分较治疗前有明显改善,与治疗前比较,具有显著性差异(P<0．05)；治疗后治疗组症状积分及KPS评分明显优于对照组,具有统计学意义( P<0．05或0．01)。毒副反应发生情况比较：治疗组恶心呕吐、口腔黏膜炎、肝损害、白细胞减少发生例数明显少于对照组,两组比较具有统计学意义(P<0．01或P<0．05)。结论化疗联合扶正抗癌方能缓解非小细胞肺癌患者临床症状,提高患者的生活质量,降低化疗的不良反应。
목적：탐토부정항암방연합화료치료비소세포폐암적림상료효。방법대본원2006년7월지2012년6월주원비소세포폐암환자67례,안조수궤수자표법분위치료조33례화대조조34례,대조조채용화료치료,치료조재대조조기출상사용부정항암방치료,치료2개주기후,관찰량조림상료효、중의증후적분、Karnofsky공능상태평분표준( KPS)평분、독부반응정황。결과근기림상료효비교：치료조유효솔위36．36%(12/33),대조조유효솔위23．52%(8/34),량조유효솔비교불구유통계학의의(χ2=0．776,P>0．05)。중의증상적분개선정황급KPS개선정황비교：치료조중의증후적분화KPS평분교치료전유명현개선,여치료전비교,구유현저성차이(P<0．05)；치료후치료조증상적분급KPS평분명현우우대조조,구유통계학의의( P<0．05혹0．01)。독부반응발생정황비교：치료조악심구토、구강점막염、간손해、백세포감소발생례수명현소우대조조,량조비교구유통계학의의(P<0．01혹P<0．05)。결론화료연합부정항암방능완해비소세포폐암환자림상증상,제고환자적생활질량,강저화료적불량반응。
Objective Objective To explore the centralizer anticancer prescription combined chemotherapy in the treatment of non-small cell lung cancer. Methods 67 cases of hospitalized patients with non-small cell lung cancer were randomly divided into treatment group according to admission order from July 2006 to June 2012, (33 cases and the control group, 34 cases in the control group with chemo-therapy treatment, the treatment group on the basis of the control group using centralizer anticancer pre-scription, after two cycles, observe clinical effect and TCM symptom score, Karnofsky functional score ( KPS) and adverse reaction conditions. Results The comparison of recent clinical curative effect: the treatment group effective rate was 36. 36% (12/33), the control effective rate was 23. 52% (8/34), two groups of efficient was not statistically significant(P<0. 05);the symptoms integral and KPS score of treat-ment group was better than control group, with statistical significance (P<0. 05 or 0. 01) . The adverse re-action comparison:the treatment group nausea and vomiting, inflammation of the oral mucosa, liver dam-age and white blood cells reduce was significantly less than the control group, the number of cases in the two groups are statistically significant ( P<0. 01 or 0. 05 ) . Conclusion centralizer anticancer prescrip-tion combined chemotherapy can alleviate clinical symptoms in patients with non-small cell lung cancer, improve the quality of life of patients and reduce the adverse reaction of chemotherapy.